Carl Nicolia

CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. There are many causes of CRS and our mission is to develop a broadly accessible treatment for multiple indications of high unmet need. Using a novel approach by calming the natural immune response to a multi organ disease, CytoAgemts' lead drug candidate, GP1681, is positioned to become a new best practice in medicine.

The BlueTree Venture Fund is a regionally-focused venture capital firm based in Pittsburgh, PA. We target early institutional investments in sectors which both match the region’s technology platform and leverage the expertise within our Fund. We seek to invest in medical technologies, software, and high-tech instrumentation companies located within 250 miles, allowing us to provide hands on mentorship and guidance. Within these sectors, we are interested in companies demonstrating compelling technologies, strong management teams, and capital-efficient business models with clear opportunities for exit through strategic acquisition.

CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. There are many causes of CRS and our mission is to develop a broadly accessible treatment for multiple indications of high unmet need. Using a novel approach by calming the natural immune response to a multi organ disease, CytoAgemts' lead drug candidate, GP1681, is positioned to become a new best practice in medicine.

The BlueTree Venture Fund is a regionally-focused venture capital firm based in Pittsburgh, PA. We target early institutional investments in sectors which both match the region’s technology platform and leverage the expertise within our Fund. We seek to invest in medical technologies, software, and high-tech instrumentation companies located within 250 miles, allowing us to provide hands on mentorship and guidance. Within these sectors, we are interested in companies demonstrating compelling technologies, strong management teams, and capital-efficient business models with clear opportunities for exit through strategic acquisition.